Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) just unveiled an update.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced the convening of its 2025 second extraordinary shareholders’ meeting on December 31, 2025, in Shanghai. The primary agenda is to consider and approve proposed amendments to the company’s articles of association, which could impact its governance structure and operational strategies.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, primarily engaged in the research, development, manufacturing, and distribution of a wide range of pharmaceutical products. The company focuses on oncology, anesthesia, and contrast agents, serving both domestic and international markets.
Average Trading Volume: 3,974,437
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$454.4B
Find detailed analytics on 1276 stock on TipRanks’ Stock Analysis page.